Investigator-assessed PFS in part D patients. Patients with anti–PD-(L)1–naive HL (A) and anti–PD-(L)1–progressed HL (B). PFS for patients with DLBCL was not captured because of low patient numbers (<0), and also because these patients were heavily pretreated. Most patients had classic HL; 2 patients with nodular lymphocyte–predominant HL were included in part D (1 in PD-(L)1–progressed and 1 in PD-(L)1–naive).